Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Morepen Laboratories approves hiving off of medical devices business
He holds a Master’s in Management from the National University of Singapore
Morepen Labs successfully raised Rs. 200 Crore through QIP
Sharma joined the Morepen Lab in 2004
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
